Ascent Group’s Maravai LifeSciences MRVI Stock Holding History

Ascent Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,764	Closed	-$41.5K	–	746
2025 Q1	$41.5K	Buy	+18,764	New	+$74.1K	﹤0.01%	692

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return

Point72 (DIFC) Dubai, United Arab Emirates $1.53B AUM 15.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ascent Group's MRVI Position: Q2 2025 in Review

Ascent Group sold out of Maravai LifeSciences (MRVI) in Q2 2025, closing a stake of 18,764 shares — an estimated $41.5K sold.

Ascent Group first reported a position in MRVI in Q1 2025 and held it in 1 quarter. The position peaked at $41.5K in Q1 2025. 150 funds tracked by Wall St. Rank hold MRVI as of Q2 2025.

Ascent Group reported no remaining Maravai LifeSciences position as of Q2 2025 after selling out during the quarter.
Ascent Group sold 18,764 Maravai LifeSciences shares in Q2 2025, an estimated $41.5K.
Ascent Group first reported a position in Maravai LifeSciences in Q1 2025 and held it in 1 quarter.
Ascent Group's Maravai LifeSciences position peaked at $41.5K in Q1 2025.
150 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2025.

Based on Ascent Group's 13F filing for Q2 2025, filed 21 Jul 2025.